Baminercept（Cat No.:I042165）is an investigational monoclonal antibody that targets the lymphotoxin beta receptor (LTβR), which is involved in immune cell signaling and inflammation. By binding to LTβR, baminercept aims to modulate immune responses and reduce inflammation, making it a potential therapeutic option for autoimmune and inflammatory diseases. It has shown promise in preclinical studies for conditions like rheumatoid arthritis and lupus, where excessive immune activation leads to tissue damage. Baminercept is being studied in clinical trials to evaluate its safety, efficacy, and potential benefits in treating chronic inflammatory conditions.
